Median Technologies, a developer of AI-powered medical imaging software, will present its latest advancements at the 2024 Radiological Society of North America (RSNA) annual meeting. The company will showcase its eyonis™ Lung Cancer Screening (LCS) software and its AI-driven imaging services for oncology drug developers. This presentation follows the successful completion of the REALITY clinical trial, which demonstrated the effectiveness of eyonis™ LCS in detecting lung cancer with statistical significance.
Positive clinical trial results validate the potential of eyonis™ LCS to improve early lung cancer diagnosis, leading to earlier intervention and potentially saving lives. This success positions Median Technologies as a key player in the growing field of AI-driven cancer diagnostics and has the potential to significantly impact lung cancer screening implementation globally. The RSNA annual meeting provides a crucial platform for the company to reach a large audience of medical professionals and industry stakeholders, potentially accelerating adoption and future collaborations.
The REALITY trial, the first of two pivotal studies, achieved its primary and secondary endpoints, showing eyonis™ LCS’s ability to effectively analyze low-dose computed tomography (LDCT) scans. This positive data reinforces the potential of eyonis™ LCS as a valuable diagnostic tool and supports the company’s plans to seek marketing authorization in the US and Europe in the first half of 2025, following the release of data from the second pivotal study, RELIVE, in Q1 2025. This planned regulatory filing represents a critical step towards commercialization and widespread availability of the technology.
The positive REALITY trial results and upcoming presentation at RSNA mark a major milestone for Median Technologies and the future of lung cancer screening. After successfully completing the second pivotal study and subsequent regulatory approvals, eyonis™ LCS could significantly improve early detection rates and improve patient outcomes. This technology has the potential to revolutionize lung cancer screening programs by offering a more accurate and efficient diagnostic tool, paving the way for broader access to early detection and potentially saving countless lives. This development could significantly alter the landscape of lung cancer diagnosis and treatment, leading to a more proactive and effective approach to combating this deadly disease. The advancement also positions Median Technologies for substantial growth and establishes them as a leader in AI-driven medical imaging solutions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
